Avalon GloboCare Partners with China (Nanjing) Cell Valley to Advance Cellular Medicines
December 20 2019 - 7:30AM
Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global
developer of cell-based technologies and therapeutics, today
announced it has established a strategic partnership with China
(Nanjing) Cell Valley (“CNCV”). CNCV is currently one of the
largest biotech zone initiatives in China with the goal of
cultivating translational research and the technological
advancement in the CellTech industry both in China and
globally. This partnership creates a platform to combine
Avalon’s clinical expertise in cellular therapy, particularly in
the Chimeric Receptor Antigen (CAR)-T area, with the
infrastructural resources available within the CNCV. Avalon
will provide their expertise in multi-center clinical studies for
cellular therapy while leveraging the immense network of affiliated
hospitals and laboratories of the CNCV. Additionally, Avalon
will collaborate with CNCV to facilitate technical training,
bio-production process standardization and harmonization.
“In conjunction with the operation of Nanjing Epicon Biotech,
which is Avalon’s core GMP bio-manufacturing facility, this
partnership with China (Nanjing) Cell Valley empowers Avalon to
further extend our repertoire of cell-based technology and
therapies, with the opportunity to streamline and expand the
bio-manufacturing throughput of our clinical-grade cellular
products, including CAR-T and stem cell-derived exosomes,” stated
David Jin, MD, PhD, President and CEO of Avalon GloboCare.
“This premiere regional hub of CellTech resources and ecosystem
will accelerate our clinical programs and contribute to Avalon’s
leading role in cellular medicines,” added Dr. Jin.
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: AVCO) is a clinical-stage,
leading CellTech bio-developer dedicated to advancing and
empowering innovative, transformative exosome technologies and
cellular therapeutics. Avalon also provides strategic advisory and
outsourcing services to facilitate and enhance its clients' growth,
development, as well as competitiveness in healthcare and CellTech
industry markets. Through its subsidiary structure with
unique integration of verticals from innovative R&D to
automated bioproduction and accelerated clinical development,
Avalon is establishing a leading role in the fields of in vitro
diagnostics (''liquid biopsy''), immune effector cell therapy
(including CAR-T/CAR-NK), and regenerative therapeutics. For more
information about Avalon GloboCare, please visit
www.avalon-globocare.com.
Forward-Looking Statements
Certain statements contained in this press release may
constitute "forward-looking statements." Forward-looking statements
provide current expectations of future events based on certain
assumptions and include any statement that does not directly relate
to any historical or current fact. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors as disclosed in our
filings with the Securities and Exchange Commission located at
their website (http://www.sec.gov). In addition to these factors,
actual future performance, outcomes, and results may differ
materially because of more general factors including (without
limitation) general industry and market conditions and growth
rates, economic conditions, and governmental and public policy
changes. The forward-looking statements included in this press
release represent the Company's views as of the date of this press
release and these views could change. However, while the Company
may elect to update these forward-looking statements at some point
in the future, the Company specifically disclaims any obligation to
do so. These forward-looking statements should not be relied upon
as representing the Company's views as of any date subsequent to
the date of the press release.
Contact Information: Avalon GloboCare Corp.4400 Route 9, Suite
3100Freehold, NJ 07728PR@Avalon-GloboCare.com
Investor Relations:Crescendo Communications, LLCTel: (212)
671-1020 Ext. 304avco@crescendo-ir.com
Avalon GloboCare (NASDAQ:AVCO)
Historical Stock Chart
From Apr 2024 to May 2024
Avalon GloboCare (NASDAQ:AVCO)
Historical Stock Chart
From May 2023 to May 2024